Importantly, this study showed that in a subgroup of patients that previously received more than three lines of therapy for metastatic cancer, 67% showed clinical benefits from the combination with venetoclax, thus indicating Bcl-2 inhibition as a potential strategy to overcome tamoxifen resistance in previously unresponsive patients [136,149]. Here, BCL2 is linked to metastatic malignant neoplasm.